Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States

RATIONALE & OBJECTIVE: Information on safety issues of newer glucose-lowering medications from a large population perspective in chronic kidney disease (CKD) patients with type 2 diabetes is limited. Our study aimed to examine hypoglycemia risk associated with sodium-glucose cotransporter 2 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310119/
https://www.ncbi.nlm.nih.gov/pubmed/35898692
http://dx.doi.org/10.1016/j.xkme.2022.100510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310119/
https://www.ncbi.nlm.nih.gov/pubmed/35898692
http://dx.doi.org/10.1016/j.xkme.2022.100510

Ejemplares similares